3 Dirt Cheap Stocks to Buy Right Now
CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics is in the process of building out a network of clinics. As those clinics open up, it'll be able to realize more revenue from its therapy.
Crispr Therapeutics: Prepare To Be Bored
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT, will generate revenue soon, with significant growth expected in 2025. The company's future potential lies in its pipeline for cardiovascular disease and cancer treatments, though these remain speculative.
1 Biotech Stock Down 62% to Buy and Hold
CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improvement.
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
3 Monster Biotech Stocks to Buy Before 2025
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
